DrugPatentWatch Database Preview
JULUCA Drug Profile
Which patents cover Juluca, and when can generic versions of Juluca launch?
Juluca is a drug marketed by Viiv Hlthcare and is included in one NDA. There are seven patents protecting this drug.
This drug has three hundred and twenty patent family members in forty-three countries.
The generic ingredient in JULUCA is dolutegravir sodium; rilpivirine hydrochloride. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; rilpivirine hydrochloride profile page.
Summary for JULUCA
| International Patents: | 320 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for JULUCA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JULUCA |
| DailyMed Link: | JULUCA at DailyMed |
Generic Entry Opportunity Date for JULUCA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for JULUCA
| Dolutegravir / rilpivirine |
| Dolutegravir and rilpivirine |
| Dolutegravir mixture with rilpivirine |
| S900007770 |
US Patents and Regulatory Information for JULUCA
International Patents for JULUCA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0923217 | ➤ Sign Up |
| Taiwan | 201030010 | ➤ Sign Up |
| Australia | 2006307101 | ➤ Sign Up |
| Singapore | 155885 | ➤ Sign Up |
| Norway | 20024126 | ➤ Sign Up |
| Cyprus | 1116331 | ➤ Sign Up |
| Japan | 2009079058 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for JULUCA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| C0073 | France | ➤ Sign Up | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE TELLES QUE LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE DE TENOFOVIR EN PARTICULIER LE TENOFOVIR DISOPROXIL FUMARATE AINSI QUE D'EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 7 | Finland | ➤ Sign Up | |
| 2012000035 | Germany | ➤ Sign Up | PRODUCT NAME: RILPIVIRIN UND DESSEN STEREOCHEMISCH ISOMERE FORMEN, SOWIE DESSEN PHARMAZEUTISCH UNBEDENKLICHE ADDITIONSSALZE, EINSCHLIESSLICH DES CHLORWASSERSTOFFSAEURESALZES VON RILPIVIRIN; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 |
| 008 | Luxembourg | ➤ Sign Up | 92008, EXPIRES: 20261128 |
| 1874117/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: DOLUTEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC 63052 08.05.2014 |
| 854 | Luxembourg | ➤ Sign Up | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE, ET TENOFOVIR, EN PARTICULIER LE FUMARATE DE TENOFOVIR DISOPROXIL |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
